Emmanuelle Charpentier and Jennifer Doudna just received a few hours ago the Nobel prize in Chemistry 2020 for “the development of a method of genome editing”, namely their 2012 discovery of the CRISPR/Cas9 genetic scissors which basically enables to “cut and paste” DNA. This scientific discovery has fueled an unprecedented biotechnology development in the past 8 years. When we started to analyze the genome editing patent landscape in Spring 2014, there were only 96 patent families(*) in our records in relation with CRISPR. We have now more than 7400 in our latest records – and adding an average of 200 more every month in 2020. What does this data tell us on who has taken advantage in engineering new life sciences solutions out of this amazing scientific discovery, now confirmed worth a Nobel Prize?Continue reading
IPStudies will be attending the next Genome Editing Applications event in Brussels, now postponed to 3 – 4 February 2016.
A number of companies identified in our CRISPR patent landscape will be speaking there, such as CRISPR Therapeutics (TJ Cradick), Cellectis (Philippe Duchateau), AstraZeneca (Lorenz Mayr), Janssen R&D (Ines Royaux), Novartis (Anett Ritter), Cellecta (Paul Diehl), Merck & Co (Myung Shin), Precision Biosciences (Victor Bartsevitch), as well as instutional applicants such as the Technical University of Denmark, the Netherlands Cancer Institute, Duke University, Wellcome Trust Sanger Institute, and Royal Holloway-University of London.
The event also features a dedicated, interactive evening seminar, discussion and dinner on Intellectual Property and Business Strategy Landscape of Genome Editing Technologies, to be lead by Dr. Philip Webber from Dehns (UK Patent and Trade Mark Attorneys). More information can be found here.
For those attending, we invite you to take this opportunity to meet our head of biotech IP analytics, Dr. Fabien Palazzoli – ask a demo of our interactive CRISPR patent landscape for genome editing R&D/IP positioning! Our free sample can be downloaded here.
Another outstanding pattern out of the CRISPR patent landscape is the complexity of inventorship and invention assignment tracking. The initial discoveries were conducted by multiple international teams; sometimes on their own, sometimes out of a formal collaborative research agreement, sometimes out of less formalized scientific research collaboration. This is again reflected in the resulting patent prosecution histories.